Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,372.00+3.36%ETH$2,422.34+5.71%GOLD$4,072.20+3.34%OIL$88.04-8.38%
Smart Investors Daily
SID Premium
AR

NASDAQ · ARQT

Arcutis Biotherapeutics, Inc.

Healthcare · Biotechnology

$32.00

Up+$2.05 (+6.41%)

Updated Nov 4, 2026, 10:13 PM

SID Score

5.9/10

Composite research score

Smart Money

58/100

Neutral

Market cap
3.3B
P/E ratio
-214.29
Dividend yield
0.00%
52-week range
$19.30 – $33.30
Volume
1.62M
Avg. volume
1.63M

Price performance · ARQT

ARQT price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

ARQT closed at $32.00 after 21 trading sessions, up 33.78% for the selected period.

Last close
$32.00
Period change
+33.78%
Period low
$23.92
Period high
$32.82
Daily close
View OHLC price history
ARQT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$31.32$32.39$31.265$32.001.62M
Nov 2, 2026$32.07$32.24$31.20$31.261.51M
Oct 30, 2026$32.335$32.69$31.67$32.071.88M
Oct 29, 2026$31.40$32.08$31.1471$31.971.75M
Oct 28, 2026$31.50$32.00$31.39$31.451.67M
Oct 27, 2026$31.40$32.11$31.1782$31.682.22M
Oct 26, 2026$31.41$32.26$31.35$31.811.55M
Oct 23, 2026$32.13$32.13$30.91$31.201.89M
Oct 22, 2026$31.68$32.50$31.35$32.202.08M
Oct 21, 2026$32.645$32.94$31.65$31.871.69M
Oct 20, 2026$31.89$33.30$31.75$32.824.49M
Oct 19, 2026$29.41$33.01$28.99$31.895.8M
Oct 16, 2026$29.18$29.37$28.15$28.821.8M
Oct 15, 2026$26.93$29.46$26.93$29.103.96M
Oct 14, 2026$26.01$26.94$25.86$26.411.65M
Oct 13, 2026$25.93$26.57$25.60$26.091.89M
Oct 12, 2026$26.54$26.815$25.97$26.221.56M
Oct 9, 2026$24.50$26.97$24.30$26.581.73M
Oct 8, 2026$23.91$24.57$23.37$24.492.61M
Oct 7, 2026$23.74$24.38$23.51$24.171.73M
Oct 6, 2026$25.37$25.37$23.885$23.922.57M

Latest ARQT news

The latest Smart Investors Daily articles mentioning ARQT.

Stock researchCompany · Overview

ARQT research

Overview

Company profile and research snapshot.

Company profile

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$32.00
Implied upside
—
Analysts
—
ARQT recent ratings
DateFirmRatingTarget
Oct 19, 2026GuggenheimBuy—
Oct 15, 2026Cantor FitzgeraldOverweight—
Aug 6, 2026Morgan StanleyOverweight—
Aug 6, 2026GuggenheimBuy—
Aug 6, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

Arcutis Appoints Rob Scott, MD to Board of Directors

WESTLAKE VILLAGE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in immuno-dermatology, today announced that Rob Scott, MD has been appointed to the Arcutis Board of Directors effective October 23, 2026. Dr. Scott is a global pharma industry leader and pioneer with over 40 years of experience inventing, advancing development for, and securing approvals of novel medici

Yahoo · Oct 27, 2026

Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference

WESTLAKE VILLAGE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the Guggenheim 3rd Annual Healthcare Innovation Conference, taking place November 9-11, 2026, in Boston. Details for the Company’s participation are as follows: Fireside Chat: Tuesday, November 10, 2026, at 10:30 a.m. ET The

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By